Vancouver, BC, May 3, 2023--Algernon Pharmaceuticals Inc., a Canadian clinical stage pharmaceutical development company, announced tioday that its subsidiary Algernon NeuroScience (AGN Neuro), has completed dosing of the second cohort in its escalating dose Phase 1 clinical study of an intravenous formulation of AP-188 ("N,N-Dimethyltryptamine" or "DMT").

Vancouver, BC, March 8, 2023--Algernon Pharmaceuticals Inc., a clinical stage pharmaceutical development company, announced that its subsidiary Algernon NeuroScience (AGN Neuro) has appointed Dr. David L. Brody as a consultant for its clinical research program for the treatment of Traumatic Brain Injury (TBI) with AP-188 ("N,N-Dimethyltryptamine or DMT").

Vancouver, BC, March 2, 2023--Algernon Pharmaceuticals Inc., a clinical stage pharmaceutical development company, announced that its subsidiary Algernon NeuroScience (AGN Neuro) has added a new clinical research program for the treatment of Traumatic Brain Injury (TBI) with AP-188 ("N,N-Dimethyltryptamine or DMT").

Vancouver, BC, February 17, 2023--Algernon Pharmaceuticals Inc., a Canadian clinical stage pharmaceutical development company, announced that its subsidiary Algernon NeuroScience (AGN Neuro), has completed dosing of the first cohort in its Phase 1 clinical study of an intravenous formulation of AP-188 ("N,N-Dimethyltryptamine" or "DMT"), a known psychedelic compound that is part of the tryptamine family.

Vancouver, BC, January 19, 2023--Algernon Pharmaceuticals Inc., a Canadian clinical stage pharmaceutical development company, announced that its subsidiary, Algernon NeuroScience (AGN Neuro), has dosed the first subject in its Phase 1 clinical study of an intravenous formulation of AP-188 ("N,N-Dimethyltryptamine" or "DMT") in the Netherlands.

Vancouver, BC, January 10, 2023--Algernon Pharmaceuticals Inc., a Canadian clinical stage pharmaceutical development company, announced that it is planning a 180 patient, 90-day Phase 2b clinical study of NP-120 ("Ifenprodil") for chronic cough to begin in Q3 of 2023.

Vancouver, BC, January 5, 2023--Algernon Pharmaceuticals Inc., a clinical stage pharmaceutical development company, announced that it has established Algernon NeuroScience (AGN Neuro), a new wholly-owned private subsidiary of AGN Pharma, to advance the Company's psychedelic DMT stroke program.

Vancouver, BC, December 20, 2022--Algernon Pharmaceuticals Inc. , a Canadian clinical stage pharmaceutical development company, announced that the United States Food and Drug Administration has granted Orphan Drug Designation (ODD) to Ifenprodil as a treatment for Idiopathic Pulmonary Fibrosis (IPF).

Vancouver, BC, September 14, 2022--Algernon Pharmaceuticals Inc. (CSE: AGN, OTCQB: AGNPF) a clinical stage pharmaceutical development company announced that it has received approval to conduct a Phase 1 clinical study of an intravenous formulation ("IVF") of AP-188 ("N,N-dimethyl tryptamine" or "DMT") for the treatment of stroke in the Netherlands from the Stichting Beoordeling Ethiek Biomedisch Onderzoek ("BEBO"), an independent Medical Research Ethics Committee ("MREC").

Vancouver, BC, June 29, 2022--Algernon Pharmaceuticals Inc. (CSE: AGN, OTCQB: AGNPF) a clinical stage pharmaceutical development company announced that its Phase 2 proof-of-concept study of NP-120 ("Ifenprodil") for idiopathic pulmonary fibrosis ("IPF") and chronic cough has reached database lock.